ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic value of circulating microRNAs for osteosarcoma in Asian populations: a meta-analysis.Clinical and experimental medicine · 2017Pooled it
- A Needle in a Haystack: The Precision of Liquid Biopsy in Finding Bone Tumors.Anti-cancer agents in medicinal chemistry · 2026Review
- Circulating miR-148a-3p Correlates with Inadequate Induction Response in Pediatric Hodgkin Lymphoma.ImmunoTargets and therapy · 2026Article
- Extracellular Vesicles in Sarcoma: Implications for Tumor Progression and Therapy.International journal of nanomedicine · 2025Review
- A comprehensive overview of liquid biopsy applications in pediatric solid tumors.NPJ precision oncology · 2024Review
- Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques.Current oncology (Toronto, Ont.) · 2024Review
- miR-148a-3p and DDX6 functional link promotes survival of myeloid leukemia cells.Blood advances · 2023Article
- Circulating and extracellular vesicle-derived microRNAs as biomarkers in bone-related diseases.Frontiers in endocrinology · 2023Review
- CircRNA 0009043 suppresses non-small-cell lung cancer development via targeting the miR-148a-3p/DNAJB4 axis.Biomarker research · 2022Article
- Cancer-Derived Extracellular Vesicles: Their Role in Sarcoma.Life (Basel, Switzerland) · 2022Review
- Liquid biopsies in primary and secondary bone cancers.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Application of miRNA Biomarkers in Predicting Overall Survival Outcomes for Lung Adenocarcinoma.BioMed research international · 2022Article
- miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6 (CDK6).Bioengineered · 2021Article
- Development of a novel necroptosis-associated miRNA risk signature to evaluate the prognosis of colon cancer patients.Annals of translational medicine · 2021Article
- miR-148a, miR-152 and miR-200b promote prostate cancer metastasis by targeting DNMT1 and PTEN expression.Oncology letters · 2021Article
- The role of microRNAs in the osteogenic and chondrogenic differentiation of mesenchymal stem cells and bone pathologies.Theranostics · 2021Review
- Identification of plasma microRNA-22 as a marker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma.The Journal of international medical research · 2020Article
- Potential diagnostic value of miRNAs in peripheral blood for osteosarcoma: A meta-analysis.Journal of bone oncology · 2020Review
- MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma.Cancer cell international · 2020Review
- Progress toward liquid biopsies in pediatric solid tumors.Cancer metastasis reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of the present study was to detect the expression levels of circulating miR-148a in the peripheral blood of osteosarcoma patients and to further investigate the clinicopathological, diagnostic, and prognostic value of miR-148a. Eighty-nine patients with initially diagnosed osteosarcoma who successfully underwent surgical resection were enrolled in this prospective study. The expression levels of circulating miR-148a were detected by real-time quantitative RT-PCR. All statistical analyses were performed with SPSS 18.0 statistical software to determine the potential values of circulating miR-148a on the clinicopathological factors, diagnosis, and prognosis. The expression levels of circulating miR-148a in osteosarcoma patients were significantly higher than that in the healthy controls (P < 0.001), and miR-148a was capable of distinguishing osteosarcoma patients from healthy controls effectively (AUC = 0.783). In addition, miR-148a expression was significantly associated with tumor size (P = 0.049) and distant metastasis (P = 0.004). Univariate survival analysis demonstrated that patients with miR-148a high expression had significantly poor overall survival (P < 0.001) and disease-specific survival (P < 0.001) after 5 years' operation. Multivariate survival analysis confirmed that miR-148a high expression was an independent predictor for unfavorable overall survival (P = 0.003) and disease-specific survival (P = 0.008), respectively. Our findings demonstrated that detection of circulating miR-148a expression in the peripheral blood have clinical potentials as an indicator of progressive phenotype, a novel diagnostic biomarker and a promising predictor to identify individuals with poor prognosis for osteosarcoma patients.
Indexed as
Identifiers
25185654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.